Resverlogix (TSX:RVX) Interest Expense : C$-2.92 Mil (TTM As of Mar. 2024)

View and export this data going back to 2005. Start your Free Trial

What is Resverlogix Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Resverlogix's interest expense for the three months ended in Mar. 2024 was C$ -0.87 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was C$-2.92 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Resverlogix's Operating Income for the three months ended in Mar. 2024 was C$ -1.50 Mil. Resverlogix's Interest Expense for the three months ended in Mar. 2024 was C$ -0.87 Mil. Resverlogix did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Resverlogix Interest Expense Historical Data

The historical data trend for Resverlogix's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Resverlogix Interest Expense Chart

Resverlogix Annual Data

Trend

Apr14

Apr15

Apr16

Apr17

Apr18

Apr19

Apr20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-7.53

-4.49

-0.93

-2.22

-2.46

Resverlogix Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial															-0.41	-0.67	-0.69	-0.69	-0.87

Resverlogix Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-2.92 Mil.

Resverlogix (TSX:RVX) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Resverlogix's Interest Expense for the three months ended in Mar. 2024 was C$-0.87 Mil. Its Operating Income for the three months ended in Mar. 2024 was C$-1.50 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was C$0.00 Mil.

Resverlogix's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Resverlogix did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Resverlogix (TSX:RVX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Resverlogix Corp (TSX:RVX) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

RVXCF:USA RFS:Germany

Address

4820 Richard Road South West, Suite 300, Calgary, AB, CAN, T3E 6L1

Website

https://www.resverlogix.com

Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.

Executives

Aaron Bradley Cann

Senior Officer

Resverlogix (TSX:RVX) Headlines

No Headlines